Schizophrenia trials in Czechia
6 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleEvenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
- Where
- Brno, Klecany, Plzen, Plzen 3, Prague 10
- Age
- 18 years and over
- People
- 135 worldwide
- Run by
- Newron Pharmaceuticals S.p.A.
See details and how to join2024-519836-18-00 · EU 2024-519836-18-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Where
- Brno, Hradec Králové, Prague
- Age
- 55 years and over
- People
- 370 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833 - Phase 3Taking peopleRelapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Where
- Brno, Klecany
- Age
- 18 years to 65 years
- People
- 472 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT07686263 · EU 2025-523664-20-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Brno-Stred, Choceň, Pardubice I, Prague
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00 - Phase 2Enrolling by invitationAn Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Where
- Brno-Stred, Choceň, Pardubice I, Prague
- Age
- 55 years to 91 years
- People
- 210 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT07459660 · EU 2025-521757-16-00 - No phaseTaking peopleSpeech-based Assessment of Relapse Risk in People With Psychosis
- Where
- Klecany
- Age
- 18 years to 65 years
- People
- 360 worldwide
- Run by
- Philipp Homan
See details and how to joinNCT07397975